Breakthrough News Ipf 2024. The fda has granted breakthrough therapy designation to bi 1015550 (boehringer ingelheim), an investigational treatment for patients with idiopathic. The landscape of idiopathic pulmonary fibrosis (ipf) treatment is poised for significant transformation, with more than 80 companies across the world developing.

Zelasudil, an experimental treatment for idiopathic pulmonary fibrosis (ipf) that’s now being tested in clinical trials, has been granted orphan drug status by the u.s. The landscape of idiopathic pulmonary fibrosis (ipf) treatment is poised for significant transformation, with more than 80 companies across the world developing.